Abstract: The invention relates to methods and devices for drug repositioning and drug repurposing as nuclear receptor modulators based on nuclear receptor cofactor testing.

Abstract: A method of treating an inflammatory disease in a subject in need thereof, comprising administering to the subject an effective amount of a glucocorticoid receptor modulator comprising a therapeutically acceptable salt, solvate, or stereoisomer thereof of Adapalene as well as pharmaceutical compositions comprising Adapalene for the management of these inflammatory diseases.

Abstract: The present invention relates to methods for measuring compound efficacy and potency on nuclear receptor-co-regulator interaction, comprising the steps of (a) co-incubating at least one nuclear receptor and at least one compound under conditions that allow interaction; (b) co-incubating the nuclear receptor-compound mixture of step (a) with an array of co-regulators, under conditions that allow compound modulated receptor-co-regulator interaction; (c) determination of compound-modulated receptor-co-regulator interaction in function B of co-regulator concentration, and (d) determination of compound-modulated receptor-co-regulator interaction in function of compound concentration; wherein steps (c) and (d) are performed in a single assay.

Abstract: The present invention relates to a method for predicting the response of a patient diagnosed with breast cancer to treatment with an endocrine therapy drug, comprising the steps of: (a) measuring the binding of the estrogen receptor, obtained from a breast cancer tumor from said patient, generating a binding profile, said binding profile comprising the binding of the estrogen receptor from said patient on one or more co-regulator proteins or functional parts thereof in the presence and absence of one or more added phosphatases, (b) measuring the binding of the estrogen receptor, obtained from a breast cancer tumor from said patient, generating a binding profile, said binding profile comprising the binding of the estrogen receptor from said patient on one or more co-regulator proteins or functional parts thereof in the presence and absence of added estradiol, and, (c) predicting from said binding profiles the response of said patient to endocrine drug therapy.

Abstract: The present invention relates to methods for identifying classification markers for tumors by monitoring the activity of protein kinases. By acquiring a phosphorylation profile of diseased and control tissue samples the method of the present invention provides classification procedures using phosphorylation patterns enabling the distinction between different types and/or sub-types of tumors. Specific classification markers for tumors can be identified enabling tumor classification, diagnosis, prognosis and/or prediction of the clinical outcome of a therapy.

Abstract: The present invention relates to systems and methods for testing kinase inhibition using an array of substrates, in particular protein kinase substrates, preferably immobilized on a porous matrix. More particularly, the method provides kinase inhibition profiles of kinase inhibitors using phosphorylation patterns. The present invention can therefore be used to predict the response of cells, tissues, organs and/or warm-blooded animals to a drug, to determine the clinical outcome of a drug therapy and for diagnostical and prognostical purposes.

Abstract: The present invention relates to methods for measuring compound efficacy and potency on nuclear receptor-co-regulator interaction, comprising the steps of (a) co-incubating at least one nuclear receptor and at least one compound under conditions that allow interaction; (b) co-incubating the nuclear receptor-compound mixture of step (a) with an array of co-regulators, under conditions that allow compound modulated receptor-co-regulator interaction; (c) determination of compound-modulated receptor-co-regulator interaction in function B of co-regulator concentration, and (d) determination of compound-modulated receptor-co-regulator interaction in function of compound concentration; wherein steps (c) and (d) are performed in a single assay.